Tomoda Y, Ohta M, Ushijuma H, Nakashima N, Chihara T, Nishi H, Tokuhashi Y, Inagaki K, Umemura S, Manabe O, Saiki N, Iida S, Okamoto M, Hori M, Arii Y, Kazeto S, Asai Y, Kobayashi I, Murase Y
Nihon Sanka Fujinka Gakkai Zasshi. 1981 Nov;33(11):1881-7.
The prognosis of patients with ovarian carcinoma is believed as worst among malignant diseases in the field of gynecology. Multiple factors including clinical stage, histologic type and grade may play an important role in the prognosis of patients. Because of these factors and the few cases of ovarian carcinoma seen in any one center over a short period, the ability to make valid evaluation of these factors has been limited. We organized ovarian tumor studying group in Tokai district with eleven member hospital and analyzed 453 cases of solid ovarian tumor retrospectively. 1) Cumulative survival rate was calculated according to the clinical stages. Five year survival rate of stage 1 was about 80%, that of stage 2 was about 30% and that of stage 3 and stage 4 were around 10% respectively. 2) Cumulative survival rate was calculated according to histologic types. There was minor variation of survival by histologic types. When we compared with different histologic types by same clinical stages such as stage 1 and stage 3 there was no definite differences of survival rate except slightly poor prognosis in case of mucinous cystadnocarcinoma. 3) Cumulative survival rate was calculated according to histologic grading. Histologic grade affects the prognosis of patients with ovarian carcinoma.
卵巢癌患者的预后被认为是妇科恶性疾病中最差的。包括临床分期、组织学类型和分级在内的多种因素可能在患者预后中起重要作用。由于这些因素以及短期内任何一个中心所见的卵巢癌病例较少,对这些因素进行有效评估的能力受到限制。我们组织了东海地区卵巢肿瘤研究小组,由11家成员医院参与,对453例实性卵巢肿瘤病例进行了回顾性分析。1)根据临床分期计算累积生存率。Ⅰ期的五年生存率约为80%,Ⅱ期约为30%,Ⅲ期和Ⅳ期分别约为10%。2)根据组织学类型计算累积生存率。组织学类型对生存率的影响较小。当我们在相同临床分期(如Ⅰ期和Ⅲ期)比较不同组织学类型时,除黏液性囊腺癌预后略差外,生存率无明显差异。3)根据组织学分级计算累积生存率。组织学分级影响卵巢癌患者的预后。